MedPath

ALEMBIC PHARMACEUTICALS LIMITED

🇮🇳India
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

16

Active:2
Completed:4

Trial Phases

3 Phases

Phase 1:2
Phase 4:4
Not Applicable:7

Drug Approvals

137

FDA:137

Drug Approvals

Amlodipine and Atorvastatin

Approval Date
May 23, 2025
FDA

Docosanol

Approval Date
May 8, 2025
FDA

Ticagrelor

Approval Date
May 5, 2025
FDA

Desonide

Approval Date
Apr 11, 2025
FDA

Lidocaine and Prilocaine

Approval Date
Apr 8, 2025
FDA

Nystatin and Triamcinolone Acetonide

Approval Date
Apr 8, 2025
FDA

CLINDAMYCIN PHOSPHATE

Approval Date
Mar 3, 2025
FDA

RIVAROXABAN

Approval Date
Jan 30, 2025
FDA

CARBOPROST TROMETHAMINE

Approval Date
Mar 15, 2024
FDA

Zolmitriptan

Approval Date
Feb 22, 2024
FDA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 14
  • Next

Clinical Trials

Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials

Not Applicable
7 (53.8%)
Phase 4
4 (30.8%)
Phase 1
2 (15.4%)
No trials found

News

Alembic Pharma Gains USFDA Approval for Diltiazem Hydrochloride ER Capsules

Alembic Pharmaceuticals has received USFDA final approval for its Diltiazem Hydrochloride Extended-Release Capsules USP, in multiple strengths.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.